Statement: the primary trial had a lower total percentage of patients experiencing adverse events compared to the secondary trial.
Primary_evidence: Adverse Events 1:   Total: 7/37 (18.92%)   gr 3port infection, 1/37 (2.70%)   flu 1/37 (2.70%)   Febrile Neutropenia 1/37 (2.70%)   gr 4 sepsis, intubated  [1]1/37 (2.70%)   Diarrhea gr 2, Nausea gr 3, infection gr 3 1/37 (2.70%)   infection normal ANC/viral grade 1 1/37 (2.70%)   Dehydration 3, Diarrhea 3, Vomit 3, HGB3, Nausea 3, K 3, Dyspnea 2 1/37 (2.70%)   gr 3cellulitis - breast 1/37 (2.70%) Adverse Events 2:   Total: 8/23 (34.78%)   gr 3port infection, 0/23 (0.00%)   flu 0/23 (0.00%)   Febrile Neutropenia 0/23 (0.00%)   gr 4 sepsis, intubated  [1]0/23 (0.00%)   Diarrhea gr 2, Nausea gr 3, infection gr 3 0/23 (0.00%)   infection normal ANC/viral grade 1 0/23 (0.00%)   Dehydration 3, Diarrhea 3, Vomit 3, HGB3, Nausea 3, K 3, Dyspnea 2 0/23 (0.00%)   gr 3cellulitis - breast 0/23 (0.00%)
Secondary_evidence: Adverse Events 1:   Total: 130/503 (25.84%)   Febrile Neutropenia21/503 (4.17%)   Neutropenia9/503 (1.79%)   Anaemia1/503 (0.20%)   Pancytopenia1/503 (0.20%)   Pericardial Effusion2/503 (0.40%)   Cardiac Failure1/503 (0.20%)   Extrasystoles0/503 (0.00%)   Vertigo1/503 (0.20%)   Nausea7/503 (1.39%)   Vomiting5/503 (0.99%)   Diarrhoea1/503 (0.20%)   Abdominal Pain1/503 (0.20%)   Ascites1/503 (0.20%) Adverse Events 2:   Total: 64/247 (25.91%)   Febrile Neutropenia3/247 (1.21%)   Neutropenia0/247 (0.00%)   Anaemia2/247 (0.81%)   Pancytopenia0/247 (0.00%)   Pericardial Effusion0/247 (0.00%)   Cardiac Failure0/247 (0.00%)   Extrasystoles1/247 (0.40%)   Vertigo0/247 (0.00%)   Nausea2/247 (0.81%)   Vomiting1/247 (0.40%)   Diarrhoea4/247 (1.62%)   Abdominal Pain3/247 (1.21%)   Ascites2/247 (0.81%)